14 May 2025 • The SECA trial has provided new insights into the management of chronic subdural hematoma (cSDH) following surgery, revealing that continuing low-dose aspirin (ASA) therapy does not impact recurrence rates.

The recurrence rates were similar between patients who continued ASA and those who discontinued it within six months (13.9 vs. 9.5%, P = 0.56). Furthermore, cardiovascular, bleeding, and mortality rates were also comparable between both groups, with event rates of 0.27 vs. 0.28, 0.10 vs. 0.08, and 0.06 vs. 0.03 per person half-year, respectively.

These findings suggest that continuing ASA may not increase risks, challenging previous assumptions about post-surgical management for cSDH patients.

Source: JAMA Neurology | Read Full Story